Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: pharmacological considerations.
Rivera
T M
TM
Emisphere Technologies, Inc., Hawthorne, New York 10532, USA.
Leone-Bay
A
A
Paton
D R
DR
Leipold
H R
HR
Baughman
R A
RA
D000284:Administration, Oral; D000818:Animals; D002210:Caprylates / Q000378:metabolism / Q000494:pharmacology*; D004338:Drug Combinations; D004386:Duodenum / Q000166:cytology / Q000187:drug effects; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007082:Ileum / Q000166:cytology / Q000187:drug effects; D007408:Intestinal Absorption / Q000187:drug effects*; D007583:Jejunum / Q000166:cytology / Q000187:drug effects; D008252:Macaca fascicularis; D008297:Male; D010314:Partial Thromboplastin Time; D051381:Rats; D017207:Rats, Sprague-Dawley; D013270:Stomach / Q000166:cytology / Q000187:drug effects
D002210:Caprylates; D004338:Drug Combinations; C111140:N-(8-(2-hydroxybenzoyl)amino)caprylate; D006493:Heparin